P

Inventor

CREW ANDREW P

US54 patents
⚠️ This page may combine multiple inventors who share the name “CREW ANDREW P”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

ARVINAS OPERATIONS INC

38 patents
US11236051B2Feb 1, 2022

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC9 citations94
US11104666B2Aug 31, 2021

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC18 citations94
US10899742B1Jan 26, 2021

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC18 citations94
US10844021B2Nov 24, 2020

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC13 citations94
US11952347B2Apr 9, 2024

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC3 citations86
US11173211B2Nov 16, 2021

Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides

ARVINAS OPERATIONS INC6 citations84
US11065231B2Jul 20, 2021

Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides

ARVINAS OPERATIONS INC16 citations83
US11964945B2Apr 23, 2024

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC2 citations73
US11384063B2Jul 12, 2022

Modulators of estrogen receptor proteolysis and associated methods of use

ARVINAS OPERATIONS INC2 citations73
US11191741B2Dec 7, 2021

Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide

ARVINAS OPERATIONS INC3 citations73
US11161841B2Nov 2, 2021

Modulators of proteolysis and associated methods of use

ARVINAS OPERATIONS INC3 citations73
US11707452B2Jul 25, 2023

Modulators of alpha-synuclein proteolysis and associated methods of use

ARVINAS OPERATIONS INC2 citations72
US11427548B2Aug 30, 2022

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC2 citations72
US10994015B2May 4, 2021

EGFR proteolysis targeting chimeric molecules and associated methods of use

ARVINAS OPERATIONS INC3 citations72
US12036209B2Jul 16, 2024

Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides

ARVINAS OPERATIONS INC2 citations70
US11912699B2Feb 27, 2024

Tau-protein targeting compounds and associated

ARVINAS OPERATIONS INC2 citations69
US12577255B2Mar 17, 2026

MDM2-based modulators of proteolysis and associated methods of use

ARVINAS OPERATIONS INC0 citations62
US12552783B2Feb 17, 2026

Modulators of proteolysis and associated methods of use

ARVINAS OPERATIONS INC0 citations62
US12427144B2Sep 30, 2025

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC0 citations62
US12312316B2May 27, 2025

Compounds and methods for the targeted degradation of androgen receptor

ARVINAS OPERATIONS INC0 citations62
US12275716B2Apr 15, 2025

Modulators of estrogen receptor proteolysis and associated methods of use

ARVINAS OPERATIONS INC0 citations62
US12239711B2Mar 4, 2025

Cereblon ligands and bifunctional compounds comprising the same

ARVINAS OPERATIONS INC0 citations62
US12171831B2Dec 24, 2024

Compounds and methods for the targeted degradation of bromodomain- containing proteins

ARVINAS OPERATIONS INC0 citations62
US12172981B2Dec 24, 2024

Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC0 citations62
US11986531B2May 21, 2024

Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides

ARVINAS OPERATIONS INC0 citations62
US11857519B2Jan 2, 2024

Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide

ARVINAS OPERATIONS INC0 citations62
US11554171B2Jan 17, 2023

Compounds and methods for the targeted degradation of bromodomain-containing proteins

ARVINAS OPERATIONS INC0 citations62
US10946017B2Mar 16, 2021

Tank-binding kinase-1 PROTACs and associated methods of use

ARVINAS OPERATIONS INC0 citations62
US10865202B2Dec 15, 2020

Indole derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC1 citations62
US12594264B2Apr 7, 2026

Modulators of alpha-synuclein proteolysis and associated methods of use

ARVINAS OPERATIONS INC0 citations61
US12264157B2Apr 1, 2025

Compounds and methods for the enhanced degradation of targeted proteins

ARVINAS OPERATIONS INC0 citations61
US11512083B2Nov 29, 2022

Compounds and methods for the enhanced degradation of targeted proteins

ARVINAS OPERATIONS INC1 citations61
US10806737B2Oct 20, 2020

Compounds and methods for the targeted degradation of fetal liver kinase polypeptides

ARVINAS OPERATIONS INC2 citations60
US12559486B2Feb 24, 2026

Tau-protein targeting compounds and associated methods of use

ARVINAS OPERATIONS INC0 citations58
US11584743B2Feb 21, 2023

Indole derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC0 citations58
US12208095B2Jan 28, 2025

Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

ARVINAS OPERATIONS INC0 citations54
US12441708B2Oct 14, 2025

Cereblon ligands and bifunctional compounds comprising the same

ARVINAS OPERATIONS INC0 citations52
US12539292B2Feb 3, 2026

BRM targeting compounds and associated methods of use

ARVINAS OPERATIONS INC0 citations51

ARVINAS INC

8 patents

OSI PHARMACEUTICALS LLC

2 patents

CREW ANDREW P

1 patent

APPARI RAMA DEVI

1 patent

Showing the top 50 of 54 patents by PatentIndex Score.